DrugDashboards

Potassium Citrate Extended Release

Potassium Citrate · POTASSIUM CITRATE 15 meq/1 · Tablet · Oral · Strides Pharma Inc.

NDC 42543-0408-01 · 100 TABLET in 1 BOTTLE · ANDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. The generic price is down 17% over the past year, to $0.1804 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.1804per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$0.6062per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$0.5233per unitnegotiated price across 5,455 plans — before rebates · Apr 1, 2026
  • Medicaid generic ceiling (FUL)$0.1804per TABweighted avg manufacturer price $0.0793 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$0.5233per unit
middle half $0.3372$0.8493 · 5,455 plans · Apr 1, 2026
Est. net of rebates
≈ $0.5233
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
99%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$1.00$2.00Sep 2017Sep 2026$0.1804
109 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$5.41
#90 count
$16.24

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$18,836
594 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

5Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 4 active manufacturers+5

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for potassium citrate (oral solid) in the next 90 days

sole-source market · price up 1% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier · median tier 3 across plans
  • Costs ≥ $950/fill · avg $94.21 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program · Xywav and Xyrem

Regulatory

Application
ANDA206813
TE code
AB
Approval date
Sep 11, 2017
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedJul 18, 2018
    VENSUN PHARMACEUTICALS INCFailed Tablet/Capsule Specifications: Tablet breakage
  • Class II · TerminatedJul 18, 2018
    VENSUN PHARMACEUTICALS INCFailed Tablet/Capsule Specifications: Tablet breakage

Manufacturers of Potassium Citrate (Tablet)

LabelerStrengthFirst seenLast seen
Bryant Ranch PrepackPOTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 3, 2026
Biocomp Pharma, Inc.POTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
Biocomp Pharma, Inc.POTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackPOTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackPOTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
Strides Pharma Inc.POTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
Strides Pharma Inc.POTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
Strides Pharma Inc.POTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
Upsher-Smith Laboratories, LLCPOTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
Upsher-Smith Laboratories, LLCPOTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Potassium Citrate Extended Release — NDC 42543-0408-01," retrieved September 3, 2026, https://drugdashboards.com/drug/42543040801.

Free to cite with attribution — see how the data is put together.